On 14 October 2026 the FDA recorded a supplement to the biologics licence application for etanercept (Enbrel, BLA 103795). The record does not state a new indication, dose or safety change. Supplements to an established biologic's licence often concern manufacturing, devices or labelling updates.
No change in prescribing follows from the record alone. Any labelling change will appear in the updated prescribing information, and biosimilar etanercept products are separate licences.
- No change to etanercept indications or dosing follows from this record alone
- Check the updated prescribing information if a labelling change is later published
- Continue standard infection screening and monitoring for patients on TNF inhibitors
Why it matters
It helps distinguish routine licence maintenance from changes that affect patients.
Don't overread it
A licence supplement is not a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free